Combretastatin A4 phosphate

Young SL, Chaplin DJ. (2004) Combretastatin A4 phosphate Background and current clinical status. Expert Opin Invest Drugs 13 1171-1182. 

West CM, Price P. Combretastatin A4 phosphate. Anticancer Drugs 2004 15 179-187. 

Combretastatin A4 phosphate (72) is a phosphate prodrug of combretastatin A4, a c/s-stilbene, isolated from Combretum caffrum (66). Combretastatin A4 is one of the many combretas-tatins that inhibits tubulin polymerization (67), shows efficacy against solid tumor, is a vascular targeting agent that blocks the blood supply to solid tumors, and is in Phase II/III clinical development for the treatment of various types of tumors as a vascular targeting agent (68-71). 

Kirwan IG, Loadman PM, Swaine DJ, Anthoney DA, Pettit 85. GR, Lippert JW, 3rd, Shnyder SD, Cooper PA, Bibby MC. Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and 86. A1 phosphate. Clin. Cancer Res. 2004 10 1446-1453. 

Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy evaluation of combretastatin A4 phosphate. Anticancer Res. 1999 19 189-195. 88. 

Dorr RT, Dvorakova K, Snead K, Alberts DS, Salmon SE, Pettit GR. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Invest. New Drugs 1996 14 131-137. 

Cooney MM, Ortiz J, Bukowski RM, et al. Novel vascular targeting/disrupting agents combretastatin A4 phosphate and related oompounds. Curr Onool Rep 2005 7 90-95. 

Badn,W., Kalliomaki, S., Widegren, B., and Sjogren, H.O. (2006). Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma. Clin. Cancer Res. 12,4714-4719. 

---